Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Multi-Center Study of the Effects of GC4419 When Administered to Reduce the Incidence and Severity of Severe Oral Mucositis Associated With Chemo RT for Locally Advanced, Non-Metastatic Head and Neck Cancer

Next Previous
Trial Profile

An Open Label Multi-Center Study of the Effects of GC4419 When Administered to Reduce the Incidence and Severity of Severe Oral Mucositis Associated With Chemo RT for Locally Advanced, Non-Metastatic Head and Neck Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avasopasem manganese (Primary) ; Cisplatin
  • Indications Head and neck cancer; Squamous cell cancer; Stomatitis
  • Focus Adverse reactions
  • Acronyms EUSOM
  • Sponsors Galera Therapeutics

Most Recent Events

  • 26 Oct 2022 Results published in the Galera media release.
  • 26 Oct 2022 According to Galeara media release, the company presented results of this study for non-small cell lung cancer at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting..
  • 26 Sep 2022 According to a Galera Therapeutics media release, data from this study will be presented at the upcoming 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top